Re: Amgen publishing on 'emerging modality', RNAi:Plasma and liver protein binding of GalNAc conjugated siRNA
I think ANG3 and PCSK9 will address different segments of the market. PCSK9 will be preferred where you need to only lower LDL. ANG3 will be preferred where there is need to lower both LDL and TG. Negative of ANG3 is that it doesn’t only reduce LDL, but it also reduces HDL by the same percentage. So the ration between LDL/HDL doesn’t change. It would take Head to Head outcome trial between PCSK9 and ANG3 to convince physicians that lowering of HDL is not an issue.